HD Insights™

Vol. 13 l Winter 2016

Issue link: http://www.e-digitaleditions.com/i/637578

Contents of this Issue


Page 15 of 19

16 HD Insights, Vol. 13 Copyright © Huntington Study Group 2016. All rights reserved. H D I N S I G H T S We spend approximately one-third of our lives asleep. Sleep quality is central to brain health, 1,2 and problems with sleep are commonly seen in most neurodegenerative disorders, 3-5 including HD. 3,6 Several studies convincingly show abnormal sleep quality in manifest HD patients, 7-12 and indicate that this happens early in the course of the disease. 13 Exactly what the first sleep problems are in HD, and whether they emerge in the premanifest stage, when other non-motor symptoms including cognitive abnormalities are already present, is unknown. Patients with HD have metabolic alterations characterized by weight loss and increased energy expenditure, 14,15 which may also relate to sleep problems, given that both are controlled by similar CNS structures, such as the hypothalamus. We therefore aimed to investigate whether sleep problems are found in premanifest patients, and if so, to characterize these problems, and evaluate whether they are associated with cognitive and/or metabolic deficits. We designed a comprehensive cognitive, sleep, and metabolic study, performed both in the field and in the laboratory, with 38 individuals with premanifest HD and 36 age- and sex-matched controls. This consisted of two weeks of actigraphy at home, allowing assessment of habitual rest-activity rhythmicity using a small, wrist-worn movement sensor; two nights of sleep study (polysomnography) and multiple sleep latency tests in the laboratory, allowing objective assessment of sleep quality, brain electric activity (EEG) and daytime sleepiness; and a body composition assessment using dual energy X-ray absorptiometry scanning. Energy expenditure was measured over 10 days at home using doubly labelled water (DLW), and for 36 hours in the laboratory by indirect calorimetry (IC). DLW is water containing a stable isotope which is administered to the patients and its elimination tracked by daily urine samples to enable estimation of metabolic rate. IC determines metabolic rate based on oxygen consumption and carbon dioxide production during rest and exercise performed in an isolated respiratory chamber. We also performed detailed cognitive and clinical assessments. We found that premanifest HD gene carriers had more disrupted sleep, characterized by a fragmented sleep profile, meaning more time spent awake during the night (see Figure); increased objective daytime sleepiness; and alterations in sleep-dependent brain activity as measured by EEG, with a clear association with increasing disease burden. In addition, the development of these abnormalities coincided with the development of cognitive, affective, and subtle motor deficits, and preceded any metabolic alterations. 16 In spite of the presence of these objectively measured sleep deficits, premanifest HD gene carriers did not complain of poorer sleep quality compared to controls, which fits with an earlier study we had done in a small group of early manifest patients who also denied any sleep problems, despite objective measures to the contrary. 13 This suggests that subjective measures of sleep quality are not necessarily helpful for research or clinical use in HD. Sleep disturbances are among the earliest non-motor symptoms in HD By: Alpar S. Lazar, PhD and Roger A. Barker, MRCP, PhD, FMedSci Figure: Representative sleep profiles of a premanifest participant and an age- and sex-matched control showing more awakenings and time spent awake during the sleep period with less REM sleep, and an overall more fragmented sleep profile in the premanifest participant. (continued on Page 20...)

Articles in this issue

Archives of this issue

view archives of HD Insights™ - Vol. 13 l Winter 2016